Ready for the Road Ahead

Impact report 2025–26

Five white lines on a blue background extending away from us on a horizontal plane, then changing direction upward and forming the shape of an upward arrow.,

« Updating the roadmap

Governance »

Ready for the road ahead

The road ahead will always hold some uncertainty as the pharmaceutical landscape is in constant flux. 

In the coming months, new therapies, evolving policy directions, and shifting global pressures will continue to reshape the environment in which we operate.

We’ll undoubtedly encounter new challenges, as well as new opportunities to collaborate, innovate, and create value. Thanks to the work we undertook in 2025–26, we’re better prepared to navigate both. 

Aerial view of a two-lane highway winding through a forest, past a body of water and toward the Rocky mountains.

Readiness is about capability, not certainty

As you’ve seen throughout this report, over the past year we deliberately strengthened capabilities that reduce the pCPA’s vulnerability to uncertainty. These are the kinds of investments that drive progress, while ensuring we can continue to move forward, even when conditions change. We’re stronger now than we were a year ago both because of what we’ve accomplished and what we’ve built — and are continuing to build.

Readiness is a mindset, not a milestone

Readiness is less about reaching a destination than embracing a continual process of becoming. Great organizations maintain readiness through ongoing learning, adaptation, and investment in the capabilities that matter most. Becoming more agile. More resilient. More responsive. More capable than yesterday and better prepared for tomorrow.

That’s the kind of organization we’re aiming to be. The realities of the road ahead will continue evolving, and so will we.

The realities of the road ahead will continue evolving, and so will we.

Looking ahead

Over the next year, we’ll continue building the specialized workforce needed to negotiate increasingly complex agreements, strengthen the systems and analytics that support informed decision-making, deepen relationships across Canada’s pharmaceutical ecosystem, and expand opportunities for knowledge sharing, engagement, and collaboration, including with international partners. 

With a new strategic plan to guide our next stage of growth, we’ll remain ready to navigate uncertainty, seize new opportunities, and continue delivering value for public drug plans and the people they serve.